<DOC>
	<DOCNO>NCT00010218</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness karenitecin treat patient relapsed refractory non-small cell lung cancer</brief_summary>
	<brief_title>Karenitecin Treating Patients With Relapsed Refractory Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate duration response patient relapse refractory non-small cell lung cancer treat karenitecin salvage chemotherapy . - Determine effect prior response chemotherapy response drug patient . - Determine survival failure-free survival patient treated drug . - Determine toxicity profile drug patient . OUTLINE : Patients stratify accord response prior chemotherapy ( relapse vs refractory ) . Patients receive karenitecin IV 60 minute day 1-5 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients respond disease 6 course may receive 2 additional course beyond best response . Patients follow every 3 month 1 year every 6 month thereafter . PROJECTED ACCRUAL : A minimum 45 patient ( 25 stratum I 20 stratum II ) accrue study within 12 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm relapsed refractory nonsmall cell lung carcinoma ( NSCLC ) Squamous cell carcinoma Basaloid carcinoma Adenocarcinoma Bronchoalveolar carcinoma Adenosquamous cell carcinoma Large cell carcinoma Large cell neuroendocrine carcinoma Giant cell carcinoma Sarcomatoid carcinoma Nonsmall cell carcinoma otherwise specify Histologic cytologic documentation recurrence require disease previously completely resect Must 1 prior chemotherapy regimen , include adjuvant neoadjuvant therapy NSCLC At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR At least 10 mm spiral CT scan Lesions consider measurable include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal mass confirm followed imaging technique Cystic lesion Tumor lesion previously irradiate area Controlled CNS metastases allow patient neurologically stable steroid PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great upper limit normal Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week mitomycin ) No prior irinotecan camptothecin drug No concurrent chemotherapy Endocrine therapy : See Disease Characteristics No concurrent hormonal therapy except noncancerrelated condition ( e.g. , insulin diabetes ) No concurrent steroid except adrenal failure Radiotherapy : See Disease Characteristics Prior radiotherapy symptomatic lesion might produce disability ( e.g. , painful bone metastasis ) allow measurable disease present At least 4 week since prior radiotherapy No concurrent palliative radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>